A5068666503- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Angiogenesis and VEGF in Cancer
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Estrogen and related hormone effects
- DNA Repair Mechanisms
- Cancer, Hypoxia, and Metabolism
- Cancer-related cognitive impairment studies
- Genetic factors in colorectal cancer
- Histone Deacetylase Inhibitors Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Diagnosis and Treatment
Indiana University Health
2016-2025
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2006-2025
Indiana University – Purdue University Indianapolis
2016-2025
Indiana University School of Medicine
2016-2025
Indiana University
2009-2024
University School
2015-2024
University of Indianapolis
2004-2024
Palmetto Hematology Oncology
2000-2023
American Society of Clinical Oncology
2001-2023
Astex Pharmaceuticals
2023
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.
This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients metastatic breast cancer previously treated an anthracycline taxane.Patients were randomly assigned receive (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone combination bevacizumab (15 mg/kg) 1. The primary end point was progression-free survival (PFS), as determined by independent review...
Metastasis of cancer cells is a complex process involving multiple steps including invasion, angiogenesis, and trafficking through blood vessels, extravasations, organ-specific homing, growth. While matrix metalloproteinases, urokinase-type plasminogen activator, cytokines play major role in invasion chemokines such as stromal derived factor-1α (SDF-1α) their receptors CXCR4 are thought to critical motility, proliferation at specific metastatic sites. We others have previously reported that...
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has associated altered risk breast cancer and variable promoter activity. Therefore, we evaluated association VEGF genotype efficacy toxicity in E2100, a phase III study comparing paclitaxel versus plus bevacizumab as initial chemotherapy metastatic
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived receptor, stem cell (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).Sixty-four previously treated anthracycline a taxane received 50 mg/d 6-week cycles (4 weeks on, then 2 off treatment). The primary end point was objective...
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated antitumor activity safety enzalutamide in locally advanced or metastatic AR-positive TNBC. Patients Methods Tumors were tested for immunohistochemistry assay optimized cancer; nuclear staining > 0% was considered positive. received 160 mg once per day until disease progression. The...
Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast cancer. This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase exemestane versus alone.Postmenopausal women ER+ advanced cancer progressing on a nonsteroidal were randomly assigned 25 mg daily plus 5 once per week (EE) or placebo (EP). The primary end point was progression-free survival...
Improved screening methods for women with dense breasts are needed because of their increased risk breast cancer and failed early diagnosis by mammography. To compare the performance abbreviated magnetic resonance imaging (MRI) digital tomosynthesis (DBT) in breasts. Cross-sectional study longitudinal follow-up at 48 academic, community hospital, private practice sites United States Germany, conducted between December 2016 November 2017 among average-risk aged 40 to 75 years heterogeneously...
To determine whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2) -targeted delivery of potent antimicrotubule agent DM1 with antitumor activity trastuzumab, is effective in patients HER2-positive metastatic breast cancer (MBC) who have previously received all standard HER2-directed therapies.In this single-arm phase II study, T-DM1 3.6 mg/kg was administered intravenously every 3 weeks to MBC had prior treatment...
Abstract Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR its variability human tumors is highly debated has been proposed as an explanation for variable responses therapeutic clinical studies. Experimental Design: We assessed the effect patients using a 64Cu-labeled nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), imaging by PET/CT....
Purpose There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), no standard care. A randomized phase II trial showed significant gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine carboplatin (GC) in clinical rate, response progression-free (PFS), overall (OS). Here, we formally compare the efficacy these regimens III trial. Patients Methods stage IV/locally recurrent TNBC who had received more than two previous...
E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared alone as initial chemotherapy for patients HER2-negative metastatic breast cancer.An independent, blinded review of radiologic clinical data was performed, assessing progression according to Response Evaluation Criteria Solid Tumors. In...
BACKGROUND Younger survivors (YS) of breast cancer often report more survivorship symptoms such as fatigue, depression, sexual difficulty, and cognitive problems than older (OS). This study sought to determine the effect age at diagnosis on quality life (QoL) by comparing 3 groups: 1) YS diagnosed 45 years or before, 2) OS between 55 70, 3) for YSs, age‐matched controls (AC) women not with cancer. METHODS Using a large Eastern Cooperative Oncology Group (ECOG) database, 505 were recruited...
A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated neoadjuvant chemotherapy. Sequencing circulating tumor DNA (ctDNA) after surgery, along enumeration cells (CTCs), may be used to detect minimal residual disease and assess which experience recurrence.To determine whether the presence ctDNA CTCs chemotherapy in TNBC is independently associated recurrence clinical outcomes.A preplanned secondary analysis was conducted from March 26, 2014,...
Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases recurrent hormone receptor-positive breast cancer.To determine whether the presence circulating tumor cells (CTCs) in a peripheral blood sample obtained approximately was associated with late clinical operable human epidermal growth factor receptor 2-negative cancer.This per-protocol secondary analysis Double-Blind Phase III Trial Doxorubicin and Cyclophosphamide Followed by Paclitaxel With...
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian pathway, a mechanism resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that plus selective ER downregulator fulvestrant would be more efficacious than alone ER-positive metastatic cancer resistant aromatase (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
Abstract Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test tracking hundreds of patient-specific mutations to detect MRD with 1,000-fold lower error rate than conventional sequencing. Experimental Design: compared our approach digital droplet PCR (ddPCR) in dilution series, then retrospectively identified two cohorts patients who had undergone prospective plasma sampling and clinical...
Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use platinum agents in TNBC basal subtype. The EA1131 trial hypothesized that disease-free survival (iDFS) would not be inferior but improved patients subtype treated compared
Abstract Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role the management of hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). The benefit continuing CDK4/6i beyond progression different ET has not been confirmed. Preclinical data suggest synergy between and PD-L1 inhibition. PACE trial prospectively evaluates whether continuation CKD4/6i palbociclib on prior aromatase inhibitor (AI), change to fulvestrant,...
Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation CDK4/6i with endocrine therapy beyond initial tumor progression or the addition checkpoint inhibitor has value in this setting.